High Patient Volume Tops Staffing Shortages as Leading Driver of Burnout in Cancer Centers
New LeanTaaS report finds 65% of cancer centers are expanding services, but leaders say scheduling and capacity management tools outrank...
Cancer
US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children as Young as 12
Eligibility extends to patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and meet HLA and MAGE-A4...
Michels Family Donates $27 Million to the Medical College of Wisconsin to Expand Personalized Cancer Care, Accelerate Cancer Research
MILWAUKEE, June 22, 2026 /PRNewswire/ -- The Medical College of Wisconsin (MCW) today announced a landmark $27 million gift from Tim...
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it...
Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical...
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there...
Onco-Innovations Announces Non-Brokered LIFE Offering
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire...
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations...
World’s 1st HIV-to-HIV Lung Transplant Performed at NYU Langone Health
NEW YORK, June 19, 2026 /PRNewswire/ -- The world's first HIV-positive-to-HIV-positive lung transplant was performed at NYU Langone Health. The...
Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical Officer
Steve van Os, MD Steve van Os, MD, appointed new Chief Medical Officer of Arlette Pharma Solutions www.arlettapharmasolutions.com Seasoned biotech...
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June...
ChemoMouthpiece, LLC Announces Partnership with Zeal Specialty Pharmacy to Support Access to the Chemo Mouthpiece® Oral Cooling Device
Partnership will support oncology practices and patients with prescribing coordination, reimbursement support, and patient onboarding services.WILMINGTON, Del., June 18, 2026...
Osteoporosis Crisis in America: New National Study Reveals Clinicians Are Failing Millions of Women After Bone Fragility Fractures
Analysis of more than 100 million insurance claims exposes a preventable epidemic: in some states, nearly 9 in 10 women...
In HelloNation, Veterinary Expert Dr. Scott Floyd Breaks Down Veterinary Costs in Oklahoma
MOORE, Okla., June 18, 2026 /PRNewswire/ -- Why do veterinary costs in Oklahoma vary so widely between clinics? According to a...
In HelloNation, Veterinary Expert Dr. Scott Floyd Breaks Down Veterinary Costs in Oklahoma
MOORE, Okla., June 18, 2026 /PRNewswire/ -- Why do veterinary costs in Oklahoma vary so widely between clinics? According to a...
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to...
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European...
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the...
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company...
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59%...